March 14th 2023
Newly published data from a phase 3 study demonstrate the safety and efficacy of fezolinetant (Astellas) for treatment of VMS due to menopause.
February 22nd 2023
February 9th 2023
Lowers sex hormone levels linked to traumatic experiencesOctober 14th 2022
Traumatic experiences are associated with lower levels of sex hormones in midlife women, especially those with short sleep, according to research presented at the North American Menopause Society Annual Meeting.
Hormone therapy linked to shoulder pain and loss of motion prevention in menopauseOctober 13th 2022
Hormone therapy was linked as a potential preventative treatment for adhesive capsulitis in menopausal women, according to a study presented at the North American Menopause Society Annual Meeting.
Which is worse: Night sweats or hot flashes?October 13th 2022
In a presentation at the North American Menopause Society Annual Meeting, investigators found these signs of menopause are 2 very separate symptoms and have different effects on stress and depression in menopausal women.
Hormone shift in menopause contributes to cardiovascular risk in aging womenMay 18th 2022
New research from a team of investigators in Europe suggests hormonal changes during menopause could explain up to 10% of the increase in LDL-C associated with the transition to menopause among aging women
Calcium supplementation could increase risk of death in older adults with cardiovascular diseaseMay 9th 2022
An analysis of data from a Cleveland Clinic database indicates calcium supplementation in older adults with aortic stenosis was linked to an increased risk of mortality and worsening aortic stenosis.
Endometriosis and early natural menopauseApril 13th 2022
Women with laparoscopically confirmed endometriosis are at significantly higher risk for early natural menopause (ENM), and this risk was greater for nulliparous women and women who never reported using oral contraceptives, according to a study in JAMA Network Open.
Fezolinetant demonstrates topline results in long-term phase 3 study for VMSMarch 11th 2022
Astellas announced positive data from its study investigating the long-term safety of fezolinetant for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
Menstrual cycle length affects future vascular healthDecember 28th 2021
According to a recent study, women who experience stable menstrual cycles during the menopause transition have a significantly higher cardiovascular disease (CVD) risk later in life than those who have a late increase in cycle length.
Midlife vision impairment and depressive symptomsDecember 2nd 2021
Midlife women with early-stage vision impairment are significantly more likely to develop depressive symptoms, according to a study in the journal Menopause, which used data from the Michigan site of the Study of Women’s Health Across the Nation (SWAN).
Menopause preparedness for patient, provider, and policymakerOctober 27th 2021
A more standardized approach to menopause preparedness, including educating both patients and providers, is needed to improve care and quality of life for individuals during and after menopause, according to a study in the journal Menopause.
Lower risk of peripheral arterial disease linked to dietary patternsJuly 29th 2021
An evaluation of multiple recommended eating patterns has found that intakes of legumes, dietary fiber, and vegetable protein is linked to lower risk of peripheral arterial disease (PAD), whereas intakes of unprocessed red meat, processed meat, and regular soft drinks are associated with higher risk.